Race's major asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II & III clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia, Breast Cancer and Ovarian Cancer.
Race owns two granted US patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Our goal is to complete bisantrene’s clinical development and make it available to new patients.
Race Oncology Limited (ASX:RAC) is pleased to announce that Dr Daniel Tillett will present at
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of
Dr. Peter Molloy has decided to step down as Managing Director and Chief Executive Officer at Race.
Race Oncology has entered into a collaborative preclinical research program with The University
Race is pleased to announce the appointment of Professor Didier Blaise to the Clinical Advisory
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific